3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Non-Small-Cell Lung
3
Head and Neck Neoplasms
2
Carcinoma, Hepatocellular
2
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Prostate Adenocarcinoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Liver Diseases
1
Liposarcoma
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Breast Neoplasms
1
Interventions
Sorafenib
4
Blood Specimen Collection
4
lenvatinib
3
sintilimab
2
halofantrine
2
camrelizumab
2
Liver Transplantation
2
Antibodies
2
trametinib
1
toripalimab
1
titanium silicide
1
tislelizumab
1
pembrolizumab
1
ledipasvir, sofosbuvir drug combination
1
genexol-PM
1
gadolinium ethoxybenzyl DTPA
1
fluorocholine
1
bavituximab
1
avatrombopag
1
aumolertinib
1
atezolizumab
1
User-Centered Design
1
Sunitinib
1
Sufentanil
1
Sofosbuvir
1
Shadowing Technique, Histology
1
Ropivacaine
1
Ribavirin
1
Radiotherapy
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Liver Diseases
×
Adjuvants, Pharmaceutic
×
Clear all
NCT04727307
2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2
Recruiting
202 enrolled